Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Denys-Drash syndrome is a rare genetic disorder of childhood characterized by nephrotic syndrome, nephroblastomas, and genital developmental abnormalities. These children present with rapidly progressive renal failure, leading to kidney transplantation at a median age of 3.6 years. In a study of the French cohort of patients with Denys-Drash syndrome, a high risk of lymphoproliferative syndrome was observed (20%). This frequency is significantly higher than in the general transplant population (4%).

The aim of the study is to evaluate the risk of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients with kidney transplant patients without Denys-Drash syndrome.

Eligibility criteria

Qualifiers

Patient must be a minor at the time of kidney transplantation

Diagnosis of Denys-Drash syndrome (WT1 pathogenic variants in exons 8 or 9) for cases

Controls: minor patient, kidney transplanted at the same center as the case, immediately before and immediately after the case

Kidney transplant recipient on immunosuppressants

Disqualifiers

History of lymphoproliferative disorder prior to transplantation

Other hematopoietic cancer

Other genetic disease with a proven increased risk of lymphoproliferative disorder

Trial design

Treatments tested in this trial

  • Collection of data from the patient's medical file

Treatment groups

108 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

URC-CIC Paris Descartes Necker Cochin

Collaborator